Definitive Contract 75A50122C00076
Award Date
9/28/22
Potential Completion Date
7/31/36
Potential Value
$299M
Awardee
Mapp Biopharmaceutical, Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
San Diego, CA 92121, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $38,243,034.02 cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Mapp Biopharmaceutical, Inc. for the development of medical countermeasures through planned clinical trials and outbreak preparedness. The contract is not set aside. The original solicitation was a Broad Agency Announcement from BARDA seeking proposals for advanced research and development of medical countermeasures against chemical, biological,...
This is a $856,704,795.58 definitive cost-plus-fixed-fee contract awarded by the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to Mapp Biopharmaceutical, Inc., a biotechnology company specializing in infectious disease treatments. The contract is for the procurement of therapeutics to address Ebola, Sudan, and Marburg viruses. There is no set-aside designation for this contract, which has an ultimate completion date of...
This is a $30,920,844.79 cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Mapp Biopharmaceutical, Inc., a biotechnology company based in San Diego, California. The contract is for the development of an Expanded Access Protocol (EAP) for ZMapp, an antibody-based therapeutic for treating viral hemorrhagic fevers such as Ebola, Sudan, and Marburg. This contract is part of the U.S. government's efforts to prepare and respond to...
This is a $149,747,956 definitive cost-no-fee contract awarded by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to the Albert B. Sabin Vaccine Institute, Inc. to advance the development of monovalent vaccines for the prevention of Marburg virus (MARV) and Sudan ebolavirus (SUDV) disease. The contract has an ultimate completion date of September 30, 2026 and was awarded on September 26, 2019. This effort is part of BARDA's...
This is a Definitive Contract awarded to Mapp Biopharmaceutical, Inc., a biotechnology company based in San Diego, California, by the Defense Health Agency, a component of the U.S. Department of Defense. The contract has a ceiling value of $1,192,803.19 and is for the BASE YEAR of the MACV Contract, which generates MACV IGG2. The contract is a Firm Fixed Price arrangement with a period of performance through March 1, 2025. There was no set-aside designation for this award. Mapp Biopharmaceutical...
This is a $30,559,760.00 cost-plus-fixed-fee delivery order awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Manufacturing Operations Baltimore LLC, a for-profit manufacturer of medical countermeasures. The contract is for the development of the MAPP biopharmaceutical Viral Hemorrhagic Fever (VHF) Medical Countermeasure (MCM) platform. This work is being performed under the Centers for Innovation in...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the Department of the Army Medical Command to Biofactura Inc., a for-profit manufacturer, to develop a process for producing an antibody-based therapy against the Marburg virus. The contract has a firm fixed price of $149,528.62 and a completion date of January 15, 2019. The contract is set aside for a small business. This SBIR Phase I award is part of the Army's efforts to advance medical countermeasures against...
This definitive, firm fixed price contract was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to the International AIDS Vaccine Initiative (IAVI) to advance the development of monovalent vaccines for prevention of Marburg virus (MARV) and Sudan ebolavirus (SUDV) disease. The contract has a ceiling value of $166,898,763.00 and a completion date of September 29, 2027. It does not have a set-aside designation. IAVI is partnering with several subcontractors,...
<p>This is a $81,976,383.00 definitive, cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian federal agency, to Public Health Vaccines LLC, a self-certified small disadvantaged business, for the advanced research and development of an RVSV-MARV vaccine. The contract has an ultimate completion date of August 31, 2027 and was awarded on February 1, 2019. The contract does not have a set-aside designation.</p>
This is a sole-source contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Ridgeback Biotherapeutics LP for the development and manufacturing of the monoclonal antibody treatment mAb114 for Ebola virus disease (EVD). The contract has a ceiling value of $159,990,035.88 and a period of performance through July 31, 2023. It was awarded on March 19, 2020 as a cost-plus-fixed-fee definitive contract. The...